DUBLIN, Oct. 23, 2019 /PRNewswire/ -- Allergan plc
(NYSE: AGN) today announced that its data will be featured during
the 2019 American Society for Dermatologic Surgery Annual Meeting
in Chicago, IL October 24-27 2019.
The meeting will be held at the Hyatt Regency Chicago and the
scheduled times (noted in local Central Time) for the Allergan
presentations are as follows:
Oral Presentations
OnabotulinumtoxinA 24 to 96 U Is Well Tolerated and Safe for
Treatment of Masseter Muscle Prominence: Results of a Phase 2
Study
- Authors: Shannon Humphrey,
Sanjay Mallya, James K. Mah, Sotirios
Tetradis, Beta Bowen, Elisabeth
Lee, Mitchell Brin
- Friday, 10/25: 3:03-3:08PM
Chin Augmentation with the Hyaluronic Acid Injectable Filler,
VYC-20L
- Authors: Kenneth Beer,
Joely Kaufman, David E. Bank, Brian S.
Biesman, Steven Dayan,
Smita Chawla, Andrew Schumacher
- Thursday, 10/24: 2:35-2:40PM
Safety and Effectivness of Hyaluronic Acid Injectable Filler,
VYC-20L, Using a Cannula for Cheek Augmentation: Results from a
Multicenter, Randomized, Single-Blind, Controlled Study
- Authors: Derek Jones,
Melanie Palm, Sue Ellen Cox, Marta
Sartor, Smita Chawla
- Friday, 10/25: 2:27-2:32PM
The Beauty Image Assessment Study: Perspectives on Facial
Aesthetics and Treatment
- Authors: Macrene Alexiades, Sabrina
Fabi, Steven Dayan,
Julius Few
- Saturday, 10/26: 1:45-1:48PM
Change from Baseline in Caliper Measurements of Submental Fat
Thickness and Probability of Response to Treatment: Post Hoc
Analyses of Pooled Data from the ATX-101 Pivotal Trials
- Authors: Leslie Baumann,
Vince Bertucci, Sachin M. Shridharani, Sara Sangha
- Friday, 10/25: 2:21-2:26PM
Clinical Benefit of ATX-101 in Treatment Nonresponders in
Reporting Treatment Satisfaction: Post Hoc Analysis of Pivotal
Trials in Patients with Moderate to Severe Submental Fat
- Authors: Shannon Humphrey,
Steven Dayan, Ashish C. Bhatia, Joel
L. Cohen, Sara Sangha
- Friday, 10/25: 2:33-2:38PM
Submental Fat Reduction Using Sequential Treatment with
Cryolipolysis and ATX-101
- Authors: Rebecca Fitzgerald, H.
Ray Jalian, Beta Bowen, Sylvia Gamio
- Friday, 10/25: 1:47-1:51PM
Poster Presentations
Greater Biological Activity and Non-Interchangeability of BOTOX®
Compared with Vacuum-Dried NABOTA®
- Authors: David Rupp,
David Canty, Catherine Rheaume, Birgitte Jacky, Ron Broide, Amy
Brideau-Andersen
- Thursday, 10/23 – Saturday, 10/26: 12:00-2:00PM
-
- Welcome Reception for questions and discussion on Thursday,
10/23: 5:30-6:30PM
Clinical Efficacy of a Novel Topical Treatment for Periocular
Dark Circles
- Authors: Lisa T. Goberdhan,
Elizabeth T. Makino, Rahul C. Mehta
- Thursday, 10/23 – Saturday, 10/26: 12:00-2:00PM
-
- Welcome Reception for questions and discussion on Thursday,
10/23: 5:30-6:30PM
Post Hoc Analysis of MRI Data from Non-responders in the Phase
3, Multicenter, Double-blind, Randomized Placebo-Controlled
REFINE-1 and REFINE-2 Trials
- Authors: Cameron D. Chestnut,
John H. Joseph, Gilly Munavalli, Jeremy
B. Green, Sara Sangha,
Elena Dimitrijevic
- Available for online viewing during program
OnabotulinimtoxinA for Treatment of Masseter Muscle Prominence:
Secondary Results from a Phase 2 Dose Escalation Study
- Authors: Jean Carruthers,
Steven Liew, Jason K. Rivers, Shyi-Gen Chen, Shannon Humphrey, Elisabeth Lee, Mitchell
F. Brin, Beta Bowen
- Available for online viewing during program
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical
leader focused on developing, manufacturing and commercializing
branded pharmaceutical, device, biologic, surgical and regenerative
medicine products for patients around the world. Allergan markets a
portfolio of leading brands and best-in-class products primarily
focused on four key therapeutic areas including medical aesthetics,
eye care, central nervous system and gastroenterology. As part of
its approach to delivering innovation for better patient care,
Allergan has built one of the broadest pharmaceutical and device
research and development pipelines in the industry.
With colleagues and commercial operations located in
approximately 100 countries, Allergan is committed to working with
physicians, healthcare providers and patients to deliver innovative
and meaningful treatments that help people around the world live
longer, healthier lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; the impact of uncertainty
around timing of generic entry related to key products, including
RESTASIS®, on our financial results; risks associated
with divestitures, acquisitions, mergers and joint ventures; risks
related to impairments; uncertainty associated with financial
projections, projected cost reductions, projected debt reduction,
projected synergies, restructurings, increased costs, and adverse
tax consequences; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Annual Report on Form 10-K
for the year ended December 31, 2018
and Allergan's Quarterly Report on Form 10-Q for the period ended
June 30, 2019. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements.
CONTACTS:
|
Allergan:
|
Investors:
|
Manisha Narasimhan,
PhD
|
(862)
261-7488
|
Media:
|
Ember
Garrett
|
(714)
246-3525
|
|
Kaetlyn
Boone
|
(714)
330-6483
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/allergan-presents-data-from-eleven-abstracts-at-the-2019-american-society-for-dermatologic-surgery-asds-in-chicago-300943617.html
SOURCE Allergan plc